{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:25:40Z","timestamp":1791951940563,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and purpose<\/jats:title>\n                <jats:p>This prospective study aimed to investigate adaptive magnetic resonance (MR)-guided stereotactic body radiation therapy (MRgSBRT) with rectal spacer for localized prostate cancer (PC) and report 1-year clinical outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Thirty-four consecutive patients with low- to high-risk localized PC that underwent 5-fraction adaptive MRgSBRT with rectal spacer were enrolled. The dosimetric comparison was performed on a risk- and age-matched cohort treated with MRgSBRT but without a spacer at a similar timepoint. Clinician-reported outcomes were based on Common Terminology Criteria for Adverse Events. Patient-reported outcomes were based on the Expanded Prostate Cancer Index Composite (EPIC) questionnaire at baseline, acute (1\u20133\u00a0months), subacute (4\u201312\u00a0months), and late (&gt;\u200912\u00a0months) phases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median follow-up was 390\u00a0days (range 28\u2013823) and the median age was 70\u00a0years (range 58\u201382). One patient experienced rectal bleeding soon after spacer insertion that subsided before MRgSBRT. The median distance between the midline of the prostate midgland and the rectum after spacer insertion measured 7.8\u00a0mm (range 2.6\u201315.3), and the median length of the spacer was 45.9\u00a0mm (range 16.8\u201362.9) based on T2-weighted MR imaging. The use of spacer resulted in significant improvements in target coverage (V100%\u2009&gt;\u200995%\u2009=\u200998.6% [range 93.4\u201399.8] for spacer vs. 97.8% [range 69.6\u201399.7] for non-spacer) and rectal sparing (V95%\u2009&lt;\u20093\u00a0cc\u2009=\u20090.7\u00a0cc [range 0\u20134.6] for spacer vs. 4.9\u00a0cc [range 0\u201312.5] for non-spacer). Nine patients (26.5%) experienced grade 1 gastrointestinal toxicities, and no grade\u2009\u2265\u20092 toxicities were observed. During the 1-year follow-up period, EPIC scores for the bowel domain remained stable and were the highest among all other domains.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>MRgSBRT with rectal spacer for localized PC showed exceptional tolerability with minimal gastrointestinal toxicities and satisfactory patient-reported outcomes. Improvements in dosimetry, rectal sparing, and target coverage were achieved with a rectal spacer. Randomized trials are warranted for further validation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-024-04784-x","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T13:02:29Z","timestamp":1708693349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["One-year clinical outcomes of MR-guided stereotactic body radiation therapy with rectal spacer for patients with localized prostate cancer"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-0743","authenticated-orcid":false,"given":"Darren M. C.","family":"Poon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oi Lei","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Yan","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Ki","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin Ting","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Ka-Fung","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Fai","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Lun","family":"Chui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiu Ming","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Kit","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kin Yin","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siu Ki","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"4784_CR1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA et al (2023) Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2214122","journal-title":"N Engl J Med"},{"key":"4784_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JU.0000000000002758","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA et al (2022) Clinically localized prostate cancer: AUA\/ASTRO Guideline, Part II: principles of active surveillance, principles of surgery, and follow-up. J Urol 208:19\u201325","journal-title":"J Urol"},{"key":"4784_CR3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","volume":"104","author":"WC Jackson","year":"2019","unstructured":"Jackson WC, Silva J, Hartman HE et al (2019) Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys 104:778\u2013789","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4784_CR4","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","volume":"23","author":"AC Tree","year":"2022","unstructured":"Tree AC, Ostler P, van der Voet H et al (2022) Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 23:1308\u20131320","journal-title":"Lancet Oncol"},{"key":"4784_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","volume":"22","author":"P Fransson","year":"2021","unstructured":"Fransson P, Nilsson P, Gunnlaugsson A et al (2021) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol 22:235\u2013245","journal-title":"Lancet Oncol"},{"key":"4784_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15821","author":"M Harvey","year":"2022","unstructured":"Harvey M, Ong WL, Chao M et al (2022) Comprehensive review of the use of hydrogel spacers prior to radiation therapy for prostate cancer. BJU Int. https:\/\/doi.org\/10.1111\/bju.15821","journal-title":"BJU Int"},{"key":"4784_CR7","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.ijrobp.2015.04.030","volume":"92","author":"N Mariados","year":"2015","unstructured":"Mariados N, Sylvester J, Shah D et al (2015) Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 92:971\u2013977","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4784_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/bju.14192","volume":"122","author":"M Chao","year":"2018","unstructured":"Chao M, Ho H, Chan Y et al (2018) Prospective analysis of hydrogel spacer for patients with prostate cancer undergoing radiotherapy. BJU Int 122:427\u2013433","journal-title":"BJU Int"},{"key":"4784_CR9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00345-018-2502-5","volume":"37","author":"M Chao","year":"2019","unstructured":"Chao M, Lim Joon D, Khoo V et al (2019) The use of hydrogel spacer in men undergoing high-dose prostate cancer radiotherapy: results of a prospective phase 2 clinical trial. World J Urol 37:1111\u20131116","journal-title":"World J Urol"},{"key":"4784_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ijrobp.2021.03.025","volume":"111","author":"MR Folkert","year":"2021","unstructured":"Folkert MR, Zelefsky MJ, Hannan R et al (2021) A multi-institutional phase 2 trial of high-dose SAbR for prostate cancer using rectal spacer. Int J Radiat Oncol Biol Phys 111:101\u2013109","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4784_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-022-02197-x","volume":"18","author":"U Bjoreland","year":"2023","unstructured":"Bjoreland U, Notstam K, Fransson P et al (2023) Hyaluronic acid spacer in prostate cancer radiotherapy: dosimetric effects, spacer stability and long-term toxicity and PRO in a phase II study. Radiat Oncol 18:1","journal-title":"Radiat Oncol"},{"key":"4784_CR12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00345-022-03953-0","volume":"40","author":"MN Alshak","year":"2022","unstructured":"Alshak MN, Eidelberg A, Diaz SM et al (2022) Natural history of lower urinary tract symptoms among men undergoing stereotactic body radiation therapy for prostate cancer with and without a rectal hydrogel spacer. World J Urol 40:1143\u20131150","journal-title":"World J Urol"},{"key":"4784_CR13","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1186\/s12885-021-08281-x","volume":"21","author":"TM Ma","year":"2021","unstructured":"Ma TM, Lamb JM, Casado M et al (2021) Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial. BMC Cancer 21:538","journal-title":"BMC Cancer"},{"key":"4784_CR14","doi-asserted-by":"crossref","unstructured":"Poon DMC, Yuan J, Wong OL et al (2021) 1.5T Magnetic resonance-guided stereotactic body radiotherapy for localized prostate cancer: preliminary clinical results of clinician- and patient-reported outcomes. Cancers (Basel) 13","DOI":"10.3390\/cancers13194866"},{"key":"4784_CR15","doi-asserted-by":"crossref","unstructured":"Poon DMC, Yuan J, Yang B et al (2022) A prospective study of Stereotactic Body Radiotherapy (SBRT) with concomitant Whole-Pelvic Radiotherapy (WPRT) for high-risk localized prostate cancer patients using 1.5 Tesla magnetic resonance guidance: the preliminary clinical outcome. Cancers (Basel) 14","DOI":"10.3390\/cancers14143484"},{"key":"4784_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","volume":"9","author":"AU Kishan","year":"2023","unstructured":"Kishan AU, Ma TM, Lamb JM et al (2023) Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: The MIRAGE randomized clinical trial. JAMA Oncol 9:365\u2013373","journal-title":"JAMA Oncol"},{"key":"4784_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13014-020-01622-3","volume":"15","author":"F Cuccia","year":"2020","unstructured":"Cuccia F, Mazzola R, Nicosia L et al (2020) Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy. Radiat Oncol 15:178","journal-title":"Radiat Oncol"},{"key":"4784_CR18","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20210521:20210521","author":"R Mazzola","year":"2021","unstructured":"Mazzola R, Sicignano G, Cuccia F et al (2021) Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intrafraction motion during 1.5 T-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer. Br J Radiol. https:\/\/doi.org\/10.1259\/bjr.20210521:20210521","journal-title":"Br J Radiol"},{"key":"4784_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.prro.2016.10.004","volume":"7","author":"BW Fischer-Valuck","year":"2017","unstructured":"Fischer-Valuck BW, Chundury A, Gay H, Bosch W, Michalski J (2017) Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall. Pract Radiat Oncol 7:195\u2013202","journal-title":"Pract Radiat Oncol"},{"key":"4784_CR20","doi-asserted-by":"publisher","first-page":"20200848","DOI":"10.1259\/bjr.20200848","volume":"94","author":"F Alongi","year":"2021","unstructured":"Alongi F, Rigo M, Figlia V et al (2021) Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes. Br J Radiol 94:20200848","journal-title":"Br J Radiol"},{"key":"4784_CR21","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.21037\/qims-21-697","volume":"12","author":"J Yuan","year":"2022","unstructured":"Yuan J, Poon DMC, Lo G, Wong OL, Cheung KY, Yu SK (2022) A narrative review of MRI acquisition for MR-guided-radiotherapy in prostate cancer. Quant Imag Med Surg 12:1585\u20131607","journal-title":"Quant Imag Med Surg"},{"key":"4784_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-03950-1","author":"DMC Poon","year":"2022","unstructured":"Poon DMC, Yang B, Geng H et al (2022) Analysis of online plan adaptation for 1.5T magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) of prostate cancer. J Cancer Res Clin Oncol. https:\/\/doi.org\/10.1007\/s00432-022-03950-1","journal-title":"J Cancer Res Clin Oncol"},{"key":"4784_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.8221","volume":"3","author":"LE Miller","year":"2020","unstructured":"Miller LE, Efstathiou JA, Bhattacharyya SK, Payne HA, Woodward E, Pinkawa M (2020) Association of the placement of a perirectal hydrogel spacer with the clinical outcomes of men receiving radiotherapy for prostate cancer: a systematic review and meta-analysis. JAMA Netw Open 3:e208221","journal-title":"JAMA Netw Open"},{"key":"4784_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028111","volume":"100","author":"HA Payne","year":"2021","unstructured":"Payne HA, Pinkawa M, Peedell C, Bhattacharyya SK, Woodward E, Miller LE (2021) SpaceOAR hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer: a systematic review. Medicine (Baltimore) 100:e28111","journal-title":"Medicine (Baltimore)"},{"key":"4784_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.860848","volume":"12","author":"MC Repka","year":"2022","unstructured":"Repka MC, Creswell M, Lischalk JW et al (2022) Rationale for utilization of hydrogel rectal spacers in dose escalated SBRT for the treatment of unfavorable risk prostate cancer. Front Oncol 12:860848","journal-title":"Front Oncol"},{"key":"4784_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.radonc.2010.04.016","volume":"95","author":"RJ Smeenk","year":"2010","unstructured":"Smeenk RJ, Teh BS, Butler EB, van Lin EN, Kaanders JH (2010) Is there a role for endorectal balloons in prostate radiotherapy? A systematic review. Radiother Oncol 95:277\u2013282","journal-title":"Radiother Oncol"},{"key":"4784_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13014-019-1346-5","volume":"14","author":"ME Hwang","year":"2019","unstructured":"Hwang ME, Mayeda M, Liz M et al (2019) Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes. Radiat Oncol 14:136","journal-title":"Radiat Oncol"},{"key":"4784_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13014-021-01834-1","volume":"16","author":"M Ogita","year":"2021","unstructured":"Ogita M, Yamashita H, Nozawa Y et al (2021) Phase II study of stereotactic body radiotherapy with hydrogel spacer for prostate cancer: acute toxicity and propensity score-matched comparison. Radiat Oncol 16:107","journal-title":"Radiat Oncol"},{"key":"4784_CR29","doi-asserted-by":"publisher","first-page":"20200433","DOI":"10.1259\/bjr.20200433","volume":"94","author":"ME Hwang","year":"2021","unstructured":"Hwang ME, Mayeda M, Shaish H et al (2021) Dosimetric feasibility of neurovascular bundle-sparing stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer to preserve erectile function. Br J Radiol 94:20200433","journal-title":"Br J Radiol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04784-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-04784-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04784-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:21:11Z","timestamp":1735852871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-04784-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4784"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-04784-x","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"28 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"97"}}